Tokushima University / Educator and Researcher Directory --- Sasa, Souichiro

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Naoki Miyamoto, Hiroaki Inoue, Tomohiro Inui, Souichiro Sasa, Mariko Aoyama, Kazumasa Okumura, Hiroaki Toba, Naoki Hino, Aya Nishisho, Yukishige Sawaka, Taeko Kawanaka, Hiromitsu Takizawa and Akira Tangoku : Absolute Lymphocyte Count Changes During Neoadjuvant Chemotherapy are Associated With Prognosis of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Patients, Clinical Breast Cancer, Vol.23, No.3, e68-e76, 2023. (Summary) Some reports have shown that absolute lymphocyte count (ALC) is associated with prognosis in breast cancer; however, the impact of ALC changes remains unclear. This study aimed to investigate the relationship between ALC changes during neoadjuvant chemotherapy for human epidermal growth factor receptor-2 (HER2)-positive breast cancer patients and disease prognosis. This retrospective cohort study January 2010 to September 2020) included patients diagnosed with HER2-positive breast cancer and treated with trastuzumab-based neoadjuvant chemotherapy. The ALC ratio was defined as the ALC value after administration of the anti-HER2 drug divided by the ALC value before administration. The optimal ALC ratio cut-off value was identified using the receiver operating characteristic curve analysis and Youden's index. The relationship between the ALC ratio and disease-free survival was assessed using the Kaplan-Meier method. Univariate and multivariate analyses were performed using the Cox proportional hazards model. Data from a total of 100 HER2-positive breast cancer patients were analyzed. The cut-off value of the ALC ratio was set as 1.142. The median follow-up period was 52.0 (range: 5.1-123.7) months. The 5-year disease-free survival rates were 88.4% and 60.9% in the high-and low-ALC ratio groups, respectively, and were significantly higher in the high-ALC ratio group (p = .0031). The ALC ratio was an independent prognostic factor in multivariate Cox proportional hazards analysis (p = .0032). HER2-positive breast cancer patients with a higher ALC ratio during trastuzumab-based neoadjuvant chemotherapy may have a better prognosis than their counterparts. (Keyword) Humans / female / Breast Neoplasms / Neoadjuvant Therapy / Retrospective Studies / Receptor, ErbB-2 / Prognosis / Trastuzumab / Disease-Free Survival / Lymphocyte Count / Antineoplastic Combined Chemotherapy Protocols (Link to Publication Site) ● Publication site (DOI): 10.1016/j.clbc.2023.01.005 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36682907 ● Summary page in Scopus @ Elsevier: 2-s2.0-85147563272 (DOI: 10.1016/j.clbc.2023.01.005, PubMed: 36682907, Elsevier: Scopus)
2.	Souichiro Sasa, Hiroaki Inoue, INUI Tomohiro, Naoki Miyamoto, Mariko Aoyama, Kazumasa Okumura, Hiroaki Toba, Takahiro Yoshida, Tezuka Miki, Hirose Chieko, Yasuyo Saijo, Hisanori Uehara, Izumori Ayumi, Takahashi Masako, Sasa Mitsunori and Hiromitsu Takizawa : Axillary lymphangioma that developed following COVID-19 vaccination: a case report, Surgical Case Reports, Vol.8, No.1, 131, 2022. (Summary) Extensive vaccination programs are being implemented worldwide for coronavirus disease 2019 (COVID-19). With the spread of vaccination, swelling of the lymph nodes after vaccination is frequently seen. We encountered a patient who developed left axillary lymphadenoma following vaccine administration. The patient was a Japanese woman in her 80 s who had previously undergone surgery for right breast cancer. She received two injections of the Pfizer-BioNTech COVID-19 vaccine in her left arm. Approximately 3 months later, she complained of left axillary swelling, and imaging resulted in a diagnosis of left axillary lymphangioma. In accordance with the patient's wishes, we performed axillary mass resection. The pathological diagnosis was lymphangioma. Our examination findings indicated that congestion of the axillary lymph vessels might have been caused by upper-arm injections of the COVID-19 vaccine. (Link to Publication Site) ● Publication site (DOI): 10.1186/s40792-022-01488-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35798903 ● Search Scopus @ Elsevier (PMID): 35798903 ● Search Scopus @ Elsevier (DOI): 10.1186/s40792-022-01488-5 (DOI: 10.1186/s40792-022-01488-5, PubMed: 35798903)
3.	Ayumi Izumori, Masako Takahashi, Souichiro Sasa, Hiroaki Inoue, Akira Tangoku, Miyuki Kanematsu and 笹三徳 : False-negatives due to poor specimens can be prevented based on the macroscopic findings for breast Vacuum-Assisted Biopsy specimens, The Journal of Medical Investigation : JMI, Vol.69, No.1.2, 51-64, 2022. (Summary) Ultrasound-guided breast tissue biopsy is an essential technique for diagnosing breast disease, but sample errors reduce its accuracy. This study investigated whether the histopathological results can be inferred from the macroscopic findings for Ultrasound-guided breast Vacuum Assisted Biopsy (VAB) specimens. Biopsy specimens from 101 patients who underwent mammary gland VAB were photographed with a smartphone, and the relationships between the macroscopic findings and the pathological results were examined. A significant difference was observed with regard to the presence/absence of turbidity: malignancy was detected in 33/37 (89%) specimens with turbidity and in 2/47 (4%) cases without turbidity (p<0.001). A significant difference was also observed regarding the surface properties:malignancy was detected in 14/70 (19%) smooth specimens and in 24/29 (83%) rough specimens (p<0.001). Also, malignancy was detected in 11/13 (85%) specimens with white spots, and the difference was significant (p<0.001). In addition, the characteristics of intraductal papilloma, fibroadenoma, and mastopathy could be confirmed by macroscopic findings. When needle-biopsy of a lesion that is targeted for resection yields macroscopic findings that match the predicted histopathological findings, it can be thought that the biopsy had been properly performed. This means that false-negatives due to poor specimens can be prevented. J. Med. Invest. 69 : 51-56, February, 2022. (Keyword) VAB / skill of the operator / histopathological findings / accuracy / sample errors (Tokushima University Institutional Repository) ● Metadata: 117012 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.69.51 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35466146 ● CiNii @ National Institute of Informatics (CRID): 1390010457641004800 ● Summary page in Scopus @ Elsevier: 2-s2.0-85128801196 (Tokushima University Institutional Repository: 117012, DOI: 10.2152/jmi.69.51, PubMed: 35466146, CiNii: 1390010457641004800, Elsevier: Scopus)
4.	Mayumi Ikeuchi, Naoki Hino, Aya Nishisyo, Mariko Aoyama, Miyuki Kanematsu, Hiroaki Inoue, Souichiro Sasa, Tomohiro INUI, Naoki Miyamoto, Kazumasa Okumura and Hiromitsu Takizawa : Drug-induced interstitial pneumonia during perioperative chemotherapy for breast cancer, The Journal of Medical Investigation : JMI, Vol.69, No.1.2, 107-111, 2022. (Summary) Drug-induced interstitial pneumonia (DIP) that occurs during chemotherapy for breast cancer is a rare but a serious adverse event. Treatments of DIP requires interruption of breast cancer treatment, which may affect the patient's prognosis. However, there are few reports which discuss DIP during breast cancer treatments. Purpose of this report is to make clear how DIP occurred and influenced breast cancer treatment in our hospital. A total of 74 patients who started perioperative chemotherapy in Tokushima Municipal Hospital for breast cancer from January 2019 to December 2020 were evaluated for DIP. Patients' and tumors' characteristics, and regimens which caused DIP were investigated. The clinical courses of the DIP patients were also followed up. Twelve of the 74 patients developed DIP. All 12 patients had histories of cyclophosphamide administration;however, the causative drug could not be determined. Ten of the 12 patients were treated with steroids, and all the patients recovered ultimately from the interstitial pneumonia. While chemotherapy was administered in six patients after mild DIP, no relapse of pneumonia was observed. DIP during perioperative chemotherapy for breast cancer was resolved with appropriate treatment. Patients were able to resume breast cancer treatment with minimal interruption. J. Med. Invest. 69 : 107-111, February, 2022. (Keyword) breast cancer / Drug-induced interstitial pneumonia / perioperative chemotherapy (Tokushima University Institutional Repository) ● Metadata: 117020 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.69.107 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35466130 ● CiNii @ National Institute of Informatics (CRID): 1390854882616723072 ● Search Scopus @ Elsevier (PMID): 35466130 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.69.107 (Tokushima University Institutional Repository: 117020, DOI: 10.2152/jmi.69.107, PubMed: 35466130, CiNii: 1390854882616723072)

Proceeding of Domestic Conference:

1.	杉本花奈乃, Hiroaki Inoue, Souichiro Sasa, Tomohiro Inui, 行重佐和香, Mariko Aoyama, Hiroaki Toba, Masakazu Goto, Yoshimi Bando and Hiromitsu Takizawa : 乳頭の硬結で発見された浸潤性小葉癌の1例, 第33回日本乳癌検診学会学術総会, Nov. 2023.
2.	行重佐和香, Hiroaki Inoue, Tomohiro Inui, Souichiro Sasa, Mariko Aoyama, Takeshi Oya, Yoshimi Bando, Masakazu Goto and Hiromitsu Takizawa : 乳腺原発神経内分泌腫瘍の1例, 第33回日本乳癌検診学会学術総会, Nov. 2023.
3.	阿部祐也, Hiroaki Inoue, Souichiro Sasa, Mariko Aoyama, Tomohiro Inui, 行重佐和香, Kazumasa Okumura, Naoki Miyamoto, Masakazu Goto, Hiroaki Toba, Takashi Kawanaka and Hiromitsu Takizawa : 顔面のしびれを契機に発見された頭蓋底骨転移に対し放射線治療が有効であった1例, 第20回日本乳癌学会中国四国地方会, Sep. 2023.
4.	細川暉雄, Tomohiro Inui, Sawaka Yukishige, Souichiro Sasa, Mariko Aoyama, Hiroaki Inoue, Hiroaki Toba and Hiromitsu Takizawa : 有害事象マネジメントにより術前ペムブロリズマブ投与を継続しpCRの診断を得たトリプルネガティブ乳癌の1例, 第20回日本乳癌学会中国四国地方会, Sep. 2023.
5.	Sawaka Yukishige, Hiroaki Inoue, Tomohiro Inui, Naoki Miyamoto, Souichiro Sasa, Mariko Aoyama, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : 高Ca血症のコントロールに難渋した乳癌多発骨転移の1例, 第98回中国四国外科学会総会/第28回中国四国内視鏡外科研究会, Aug. 2023.
6.	Hiroaki Inoue, Souichiro Sasa, Mariko Aoyama, Tomohiro Inui, Sawaka Yukishige, Naoki Miyamoto, Hiroaki Toba, Masakazu Goto and Hiromitsu Takizawa : 高齢乳癌患者におけるCDK4/6阻害剤投与の検討, 第98回中国四国外科学会総会/第28回中国四国内視鏡外科研究会, Aug. 2023.
7.	Tomohiro Inui, Hiroaki Inoue, Souichiro Sasa, Kazumasa Okumura, Mariko Aoyama, Sawaka Yukishige, 井﨑富由実, Naoki Miyamoto, Hiroaki Toba, Yoshimi Bando and Hiromitsu Takizawa : 当院における肉芽腫性乳腺炎治療の検討, 第31回日本乳癌学会学術総会, Jun. 2023.
8.	Sawaka Yukishige, Tomohiro Inui, Souichiro Sasa, Mariko Aoyama, Hiroaki Inoue, Kazumasa Okumura, Masakazu Goto, Hiroaki Toba, Hiromitsu Takizawa, 甫喜本憲弘 and 頼田顕辞 : 局所皮弁による再建を行った腋窩副乳癌の1例, 第31回日本乳癌学会学術総会, Jun. 2023.
9.	Mariko Aoyama, Hiroaki Inoue, Tomohiro Inui, Souichiro Sasa, Kazumasa Okumura, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : トリプルネガティブ乳癌におけるHER2低発現の有無による臨床病理学的所見と予後の検討, 第31回日本乳癌学会学術総会, Jun. 2023.
10.	Hiroaki Inoue, Souichiro Sasa, Kazumasa Okumura, Mariko Aoyama, Tomohiro Inui, Sawaka Yukishige, 井﨑富由実, Naoki Miyamoto, Hiroaki Toba and Hiromitsu Takizawa : 高齢乳癌患者におけるCDK4/6阻害剤投与の検討, 第31回日本乳癌学会学術総会, Jun. 2023.
11.	Sawaka Yukishige, Hiroaki Inoue, Tomohiro Inui, Souichiro Sasa, Mariko Aoyama, Kazumasa Okumura, Hiroyuki Morino, 吉田友紀子, 宮本容子 and Hiromitsu Takizawa : BRCA遺伝学的検査の結果inconclusiveとなった3例, 第29回日本遺伝性腫瘍学会学術集会, Jun. 2023.
12.	Hiroaki Inoue, Souichiro Sasa, Tomohiro Inui, Mariko Aoyama, Kazumasa Okumura, Naoki Miyamoto, Hiroaki Toba, Yoshimi Bando and Hiromitsu Takizawa : 針生検における非浸潤癌周囲のTILsは浸潤癌の存在を予測できるか, 第123回日本外科学会定期学術集会, Apr. 2023.
13.	Hiroyuki Sumitomo, Hiroaki Toba, 井﨑富由実, Taihei Takeuchi, Tomohiro Inui, Shin-ichi Sakamoto, Naoki Miyamoto, Souichiro Sasa, Mariko Aoyama, Hiroaki Inoue, Mika Takashima, Seiya Inoue, Naoya Kawakita, Satoshi Fujiwara, Masakazu Goto, Kazumasa Okumura, Yukikiyo Kawakami and Hiromitsu Takizawa : 大きな縦隔腫瘍に対する気縦隔を用いた縦隔鏡アプローチの有用性, 第123回日本外科学会定期学術集会, Apr. 2023.
14.	Souichiro Sasa, Hiroaki Inoue, INUI Tomohiro, Naoki Miyamoto, Mariko Aoyama, Kazumasa Okumura, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : 原因不明の発熱により治療方針決定に難渋した局所進行乳癌の一例, 第32回日本乳癌検診学会学術総会, Nov. 2022.
15.	Hiroaki Inoue, Souichiro Sasa, Tomohiro Inui, Mariko Aoyama, Kazumasa Okumura, Hiroyuki Sumitomo, Naoki Miyamoto, Hiroaki Toba, Yuka Hiroshima and Hiromitsu Takizawa : 当院におけるトモシンセシスガイド下マンモトーム生検の経験, 第32回日本乳癌検診学会学術総会, Nov. 2022.
16.	Souichiro Sasa, Hiroaki Inoue, Tomohiro Inui, Mariko Aoyama, Kazumasa Okumura, 板東真由, Ichiro Hashimoto, Atsuko Yoshida, 山口美代子, Hiroaki Toba, Masakazu Goto and Hiromitsu Takizawa : 多診療科・多職種チーム連携が有用であった妊娠期乳癌の1例, 第10回日本乳房オンコプラスティックサージャリー学会総会, Oct. 2022.
17.	Hiroaki Inoue, INUI Tomohiro, Souichiro Sasa, Mariko Aoyama, Kazumasa Okumura, Naoki Miyamoto, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : 骨髄癌症，硬膜下血腫によりoncological emergencyの状態であったが救命し得た乳癌多発骨転移の1例, 第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会, Sep. 2022.
18.	Mariko Aoyama, Hiroaki Inoue, INUI Tomohiro, Souichiro Sasa, Kazumasa Okumura, Hiroaki Toba, Takahiro Yoshida and Hiromitsu Takizawa : 3次治療でオラパリブが著効したBRCA陽性転移再発乳癌の1例, 第30回日本乳癌学会学術総会(ハイブリッド開催), Jun. 2022.
19.	Kazumasa Okumura, INUI Tomohiro, Souichiro Sasa, Mariko Aoyama, Hiroaki Inoue, Hiroaki Toba, Takahiro Yoshida, Hiromitsu Takizawa and Akira Tangoku : ペムブロリズムマブの免疫関連副作用と考えられた甲状腺中毒，DICを発症しステロイドが著効した1例, 第30回日本乳癌学会学術総会(ハイブリッド開催), Jun. 2022.
20.	INUI Tomohiro, Hiroaki Inoue, Souichiro Sasa, Mariko Aoyama, Kazumasa Okumura, Naoki Miyamoto, Hiroaki Toba, Hiromitsu Takizawa and Akira Tangoku : 薬剤性肝障害を来したがCDK4/6阻害薬を変更し治療継続し得た2例, 第30回日本乳癌学会学術総会(ハイブリッド開催), Jun. 2022.
21.	Souichiro Sasa, Hiroaki Inoue, INUI Tomohiro, Naoki Miyamoto, Mariko Aoyama, Kazumasa Okumura, Takahiro Yoshida, Hiroaki Toba and Hiromitsu Takizawa : 当院におけるコンパニオン診断目的に行われたBRCA1/2遺伝学的検査の現状とオラパリブの使用経験, 第30回日本乳癌学会学術総会(ハイブリッド開催), Jun. 2022.
22.	Hiroaki Inoue, 山下華乃, Souichiro Sasa, INUI Tomohiro, Mariko Aoyama, Kazumasa Okumura, Naoki Miyamoto, Hiroaki Toba, Takahiro Yoshida, Yoshimi Bando, Hiromitsu Takizawa and Akira Tangoku : 非浸潤癌におけるTILsは浸潤の有無を予測できるか, 第30回日本乳癌学会学術総会(ハイブリッド開催), Jun. 2022.
23.	Hiroaki Inoue, Souichiro Sasa, INUI Tomohiro, Mariko Aoyama, Kazumasa Okumura, Naoki Miyamoto, Hiroaki Toba, Takahiro Yoshida and Hiromitsu Takizawa : エリブリン投与中の末梢血総リンパ球数変化率は進行・再発乳癌の予後予測因子となるか, 第122回日本外科学会定期学術集会(ハイブリッド開催), Apr. 2022.

Et cetera, Workshop:

1.	Souichiro Sasa : 乳がん診療最前線∼遺伝性乳癌卵巣癌症候群を中心に∼, 第30回徳島大学病院がん診療連携セミナー, Mar. 2024.
2.	Masakazu Goto, Seiya Inoue, Satoshi Fujiwara, 髙杉遥, 細川暉雄, Sawaka Yukishige, Taihei Takeuchi, Tomohiro Inui, Hiroyuki Sumitomo, Naoki Miyamoto, Shin-ichi Sakamoto, Souichiro Sasa, Atsushi Morishita, Mariko Aoyama, Hiroaki Inoue, Naoya Kawakita, Hiroaki Toba and Hiromitsu Takizawa : 当院における腹臥位胸腔鏡下食道亜全摘術の術後短期成績について, 第36回四国内視鏡外科研究会, Mar. 2024.
3.	Souichiro Sasa : 正しく受けよう，乳がん検診, ピンクリボンとくしま2023, Oct. 2023.
4.	Souichiro Sasa : 当院でのTNBC周術期治療の現状, ICI Conference for perioperative TNBC in Tokushima, Jul. 2023.
5.	Souichiro Sasa : 進行再発HER2陽性乳癌に対する当院での治療と副作用マネジメントを再考する, Breast Cancer Web Seminar in Tokushima(ハイブリッド形式), Mar. 2023.
6.	住友弘幸, Masakazu Goto, Seiya Inoue, Satoshi Fujiwara, 井﨑富由実, 行重佐和香, 竹内大平, Tomohiro Inui, Shin-ichi Sakamoto, Naoki Miyamoto, Souichiro Sasa, 三崎万理子, Hiroaki Inoue, Mika Takashima, Naoya Kawakita, Kazumasa Okumura, Hiroaki Toba and Hiromitsu Takizawa : 食道癌術後，再建胃管穿孔による右膿胸を生じた1例, 第6回徳島外科医会, Feb. 2023.
7.	Souichiro Sasa : 早期発見のカギブレスト・アウェアネス, 徳島ピンクリボン集会2022, Oct. 2022.
8.	井﨑富由実, Hiroaki Inoue, Tomohiro Inui, Souichiro Sasa, Mariko Aoyama, Naoki Miyamoto, Kazumasa Okumura, Hiroaki Toba, Masakazu Goto, 住田智志, Yoshimi Bando and Hiromitsu Takizawa : 巨大石灰化を認めた骨・軟骨化生を伴う乳癌の1例, 第19回日本乳癌学会中国四国地方会, Sep. 2022.
9.	青山理央, Souichiro Sasa, Tomohiro Inui, Mariko Aoyama, Kazumasa Okumura, Hiroaki Inoue, Hiroaki Toba, Masakazu Goto, Takeshi Oya and Hiromitsu Takizawa : 乳腺腺様嚢胞癌の一例, 第19回日本乳癌学会中国四国地方会, Sep. 2022.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

薬剤耐性トリプルネガティブ乳癌に対するmiRNA-433-3p補充療法の可能性 (Project/Area Number: 24K11742 )
iPS細胞から誘導した気管支肺胞幹細胞を用いたがん幹細胞研究 (Project/Area Number: 23K08319 )
Search by Researcher Number (30834915)

Designated Assistant Professor : Sasa, Souichiro

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

Proceeding of Domestic Conference:

Et cetera, Workshop:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)